Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Influenza, Human

Treatments: Drug: Zanamivir hydrate

Study type: Observational

Funder types: Industry

Identifiers

NCT01390792

112316

Details and patient eligibility

About

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Enrollment: 622 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who meet the study population criteria

Exclusion criteria

• Subjects with a history of hypersensitivity to the ingredients of zanamivir

Trial design

622 participants in 1 patient group

Subjects prescribed zanamivir

Description:

Subjects prescribed zanamivir during study period

Treatment:

Drug: Zanamivir hydrate